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Abstract
Background: Technologies based on DNA microarrays have the potential to provide detailed information on genomic
aberrations in tumor cells. In practice a major obstacle for quantitative detection of aberrations is the heterogeneity of
clinical tumor tissue. Since tumor tissue invariably contains genetically normal stromal cells, this may lead to a failure to
detect aberrations in the tumor cells.
Principal Finding: Using SNP array data from 44 non-small cell lung cancer samples we have developed a bioinformatic
algorithm that accurately models the fractions of normal and tumor cells in clinical tumor samples. The proportion of
normal cells in combination with SNP array data can be used to detect and quantify copy number neutral loss-of-
heterozygosity (CNNLOH) in the tumor cells both in crude tumor tissue and in samples enriched for tumor cells by laser
capture microdissection.
Conclusion: Genome-wide quantitative analysis of CNNLOH using the CNNLOH Quantifier method can help to identify
recurrent aberrations contributing to tumor development in clinical tumor samples. In addition, SNP-array based analysis of
CNNLOH may become important for detection of aberrations that can be used for diagnostic and prognostic purposes.
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Introduction
Bioinformatic algorithms have been developed to use SNP array
information to identify genomic aberrations such as DNA copy
number changes and loss-of–heterozygosity (LOH), i.e. stretches of
DNA with exclusively homozygous markers [1–8]. However, one
major drawback of these methods is that genetic heterogeneity in
tumor samples, caused by the mixture of cancer and stromal cells,
is often not taken into account. As a consequence aberrations are
often not detected in samples with a large proportion of genetically
normal cells. This may partly explain why, despite the accumu-
lation of large amounts of genomic data, the clinical impact of such
analyses for diagnostic purposes is still small. Tumor tissue
represents a mixture of tumor and non-tumor cells, i.e.
inflammatory cells, stromal fibroblasts and cells of blood- and
lymph vessels [9]. The fraction of normal cells often exceeds the
fraction of tumor cells in patient samples stored in biobanks
(Figure 1A). This sample heterogeneity severely affects copy
number analysis. To the best of our knowledge there are no
estimates on how the sensitivity of detection of genomic
aberrations depends on the proportion of normal cells in clinical
tumor samples. One reason may be the difficulty to estimate the
tumor vs. normal cell ratio histologically by microscopy in
heterogeneous tumor samples with varying proportions of normal
cells in different parts of the sample. Moreover, there is a lack of
consensus on how tumor cell content in a solid cancer should be
assessed and annotated. Thus, the performance of the current tools
for detection of genomic aberrations in clinical tumor samples is
often uncertain.
A recently developed tool takes sample heterogeneity into
account for identification of copy number states [10]. It is designed
for studies with paired samples (tumor and normal). In practice,
however, paired samples are often not available for larger patient
cohorts.
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of allele frequencies depending on varying proportions of normal
cells in the tumor sample using simulations [11].
Another promising analytical tool, AsCNAR, is able to identify
LOH even when one of two mixed cell lines is present only in a
proportion of about 20% [12]. Recently Assie et al described an
algorithm that take tumor heterogeneity into account in
identifying genomic aberrations in samples with 40–75% of tumor
cells [13].
Studies suggest that copy number neutral LOH can be a
mechanism for inactivation of tumor suppressor genes [14].
Several studies and our own data suggest that CNNLOH is more
common than previously thought [15,16]. Taken together this
suggests that CNNLOH may be important in determining certain
cancer phenotypes. To analyze CNNLOH on a genome-wide
scale in the tumor cells in heterogeneous samples we focused on 1)
developing an algorithm to quantify the proportion of normal cells
in the sample and 2) to quantify CNNLOH throughout the
genome in the tumor cells. Such quantitative analysis has the
potential to become an important tool for molecular cancer
diagnostics.
Results
A strategy for quantification of CNNLOH in
heterogeneous tumor samples
To quantitate CNNLOH in heterogeneous tumor samples the
allele-specific signal contribution from different types of cells need
to be estimated. Figure 1 illustrates a typical mixture of cells in
frozen sections of a non-small cell lung cancer (NSCLC) tumor
sample and provides a schematic representation of the different of
types of cells and genotypes that could be present in the event of a
genomic deletion or CNNLOH. Other genomic aberrations,
including those giving rise to higher ploidy aberrations, may also
occur at the same locus as the deletion or CNNLOH, further
complicating the picture. However, the likelihood of such events
can be expected to be low and in this study they have been
assumed to be negligible in comparison to the effects of deletions
and CNNLOH.
The fraction of normal cells can for some types of tumors be
measured in a straightforward manner. In hematological tumors
the fraction of normal cells can be measured using flow cytometry
employing informative surface markers. However, single cell
suspensions for flow cytometry are difficult to obtain from solid
tumors. Alternatively, automated or manual means of identifying
normal cells by counting them in situ based on molecular markers
or morphology may be used. These methods require advanced
imaging techniques or time consuming work for a trained
histopathologist. In this paper we use the signal intensities from
the two SNP alleles to estimate the fraction of normal cells and use
that information to estimate the proportion of tumor cells with
CNNLOH.
Quantification of the proportion of normal cells from SNP
genotyping array data
In samples where the proportion of normal cells is difficult to
obtain by other means, we set out to estimate the fraction of
normal cells from SNP data only. As shown in Fig. 1B the fraction
of cells with 2N DNA (C2N) in regions with deletions is the sum of
the normal cells (Nnormal) and the tumor cells with 2N DNA (T2N).
The basis for the CNNLOH Quantifier method is to use the allele-
specific signals A and B for each locus to obtain the experimental
Allele B frequency (ABf), as a normalized ratio of B/(A+B) see
METHODS. A derivation and a graphical illustration are
available elsewhere [17]. The ABfs of heterozygous informative
markers in complex tumor samples depend on copy number and
Figure 1. Tumor sample heterogeneity. A) Hematoxylin-eosin stained frozen section of a representative NSCLC case analysed in this study
(original magnification 406). The tumour sample is composed of a mixture of tumor cells white arrow, stroma with a blood vessel black arrow,
inflammatory cells, i.e lymphocytes red arrow, and a remaining lung alveolus filled with macrophages green arrow. B) Deletion LOH. Normal cells are
indicated by oval cell shape. The deleted region in the tumor cells (rectangular cell shape) is indicated by white circles. Schematic chromosome pairs
with only informative markers A for the black and B for the red chromosme. Below each chromosome the genotype in the area of the deletion is
indicated. Cells with different copy number genotypes are labelled Nnormal,T 2N,T 1N, and T0N. N indicates that the cell is normal and T that it sis a
tumor cell. The subscripts for the tumor cells indicate the DNA content in the region with deletion. Since these are all the cell types in the sample the
proportions sum up to one. C) Copy neutral LOH. In this case the tumor cells all have 2N DNA content. However, some tumor cells are homozygous
(in this case BB) for the region of interest (Thom) and the other type is heterozygous AB (Thet). The sum of the fractions of cells equals one.
doi:10.1371/journal.pone.0006057.g001
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identify the proportion of C2N cells by comparing the experimental
ABfs in a window of consecutive SNPs in regions with mono-allelic
deletions with simulated data. The simulations take factors into
account such as average heterozygosity, tumor cell copy number,
experimental variation and the composition of diploid cells and
tumor cells. Figure 2 illustrates how histograms of observed ABfs
are compared to simulated histograms with varying fractions of
C2N using the Euclidean distance. The histogram with the smallest
distance to the observed histogram identifies the corresponding
C2N (see Fig. 2 and METHODS).
Nnormal is not obtained directly from the estimate of C2N.
However, since the normal cells can be expected to have two of
each autosome their contribution to the ABf is expected to be
equally large for all autosomes, while the additional contribution
of T2N cells may vary with the tumor heterogeneity for each
chromosome. Thus, in samples where copy number loss is
detected on several chromosomes the lowest estimate of C2N for
a chromosome has the smallest contribution from 2N tumor cells.
In many cases where the deletion has caused a proliferation
advantage the contribution to the smallest C2N from 2N tumor
cells will with time be close to zero. Therefore in cases where
information from several chromosomes is available it may be
justified to estimate Nnormal as the smallest C2N.
Validation of SNP array based estimates by comparison
to manual counting of normal cells
We applied the method to 60 non-small cell lung cancer samples
(see METHOD). Forty-four out of sixty samples (73%) met the
arbitrary criteria that at least two regions on two different
chromosomes varied no more than 5% in their C2N estimates and
that could be used to provide an estimate of Nnormal (see
METHODS). The criteria have been set to take into account
the possible effect of constitutive allelic patterns resembling
CNNLOH. Most of the 16 cases for which no estimate could be
obtained did not have two deletions.
In order to validate the estimates of the normal cell fraction
based on the SNP data, a random subset of the 60 NSCLC
samples were selected for careful and extensive microscopic
counting of normal and tumor cells in frozen sections (see
Figure 2. Estimation of the proportion of heterozygous cells. Two examples of observed ABf values along chromosomes. Windows of at least
140 consequtive SNP markers are used to gather allele-specific information along the chromosome. The ABf values in each window are illustrated as
an observed histogram. In the next step the observed histogram is compared to hundreds of simulated histograms where the fraction of
heterozygous cells has been varied. The simulated histogram with the shortest Euclidean distance to the observed histogram identifies the most
likely proportion of heterozygous cells in the sample (X%). The comparison of histograms is used both for estimation of the proportion of diploid cells
(C2N) in regions where tumor cells have deletions and the proportion of heterozygous cells (Chet) in genomic regions with 2N tumor cells. C2N and Chet
are subsequently use for estimation of the fraction of normal cells and quantification of CNNLOH.
doi:10.1371/journal.pone.0006057.g002
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cases where Nnormal could be estimated, Table 1 shows the
estimates of the fraction of normal cells obtained using SNP array
data and manual counting based on morphology for these
samples. There is good agreement between the results obtained
by the two methods, which indicates that the SNP based method
provides accurate information on the fraction of normal cells in
tumor samples.
Quantitation of copy number neutral LOH in lung cancer
samples
It is necessary to quantify the fraction of normal cells present in
a tumor sample before information from SNP array analysis can
be used to estimate the fraction of tumor cells with 2N DNA that
has LOH, i.e. CNNLOH. CNNLOH = Thom/(Thom+Thet). (see
Fig. 1B). In this case it is the heterozygous tumor cells Thet that
together with the normal cells will modify the Allele B frequency of
the homozygous tumor cells with LOH. For CNNLOH the Allele
B frequency of the informative markers depends on the
heterozygous cells Chet. Simulated histograms taking varying
fractions of heterozygous cells into account were compared to
histograms based on ABf values from a moving window with a
fixed number of markers (see Fig. 2 and METHODS). The
simulated histogram most similar to the observed histogram,
identified the corresponding fraction of heterozygous cells, Chet.I f
the fraction of normal cells Nnormal is known, CNNLOH can be
calculated, since 1= Nnormal + Thom+Thet. To demonstrate the
value of CNNLOH Quantifier method we applied it to a set of
NSCLC samples (see METHODS). Genome-wide quantitative
measurements of CNNLOH are shown in Fig. 3. It can be noted
that there are recurring regions with high degrees of copy number
neutral LOH. One example on chromosome 11 is shown in Fig. 3.
Future work will be focused on elucidating the importance of copy
number neutral LOH in such regions for tumor development. For
comparison CNNLOH was also analyzed in 60 normal reference
samples (see Fig. S1).
Quantification of CNNLOH – comparison between FISH
and SNP data
In order to study the accuracy of the quantification of
CNNLOH we wanted to compare the results to those obtained
with an independent method. Gunnarsson et al have measured the
presence of small deletions on 13q14 in tumor cell preparations
from patients with chronic lymphocytic leukemia (CLL) using
fluorescence in situ hybridization (FISH) [18]. In two cases tumor
cells had acquired two copies of chromosome 13 with an internal
13q14 deletion. Thus, in these cases the proportion of CLL cells
with zero and one FISH signal represent the homozygous and
heterozygous tumor cells respectively. An estimate of the
CNNLOH on chromosome 13 outside of the deleted region on
13q14 can be obtained as the proportion of cells with zero signal
on 13q14 divided by the sum of the proportions with zero and one
signal. Due to too few regions with deletions the proportion of
normal cells could no be obtained from the SNP data. Instead flow
cytometry data from Gunnarsson et al 2008 provided this
information. Thus, the proportion of normal cells from flow
cytometry and SNP array data for the two samples was used to
quantify CNNLOH. Table 2 shows the estimates of CNNLOH
obtained by the two methods. It can be noted that the estimates
only differ by 4 and 6% in the two samples, which indicates that
the measurement of CNNLOH is accurate.
Quantification of CNNLOH is robust to variations in
sample purity
An important requirement for the quantification of CNNLOH
is that the method should be robust and not influenced by the
fraction of normal cells in the sample. In order to test the
performance of the algorithm we varied the fraction of normal
cells in a tumor sample by enriching for tumor cells. In five cases
6 000–10 000 tumor cells were selected using laser microdissection
(see METHODS). Standard Affymetrix SNP array analysis was
performed on DNA from these tumor-enriched preparations. The
fraction of normal cells and tumor LOH for copy number neutral
regions was quantified and the results were compared to the results
from crude tumor samples (Fig. 4). The measurements of
CNNLOH in the crude samples appear to be highly consistent
with those in the microdissected samples. In order to quantify the
performance of CNNLOH detection we chose to count the
number of chromosomal segments in Fig. 4 that had tumor LOH
higher than an arbitrarily set threshold, in this case 0.5 in both
samples. This procedure provides a rough estimate of the ability to
detect CNNLOH. Table 3 shows the ratio of number of segments
that were detected in the microdissected sample compared to the
whole sample. The ratio is close to one for all samples indicating
that approximately the same numbers of segments are detected
irrespective of fraction of normal cells that varied between 1% and
26%. It could be argued that the fraction of normal cells is so low
that it is difficult to observe any difference between the pairs of
samples. However, studying the robustness of copy number
detection it can be noted that in three pairs of samples (13A,
296A and 319A) there was a dramatic reduction (up to 122-fold) in
the number of segments detected as bearing copy number
aberrations in the whole sample (see Table 3.). In summary, the
analysis of CNNLOH appears to be robust, while copy number
detection may be highly influenced even by a proportion of
normal cells in the range of 1–26%, which is modest for many
types of clinical tumor specimens.
Performance of CNNLOH detection on simulated data of
mixtures of normal and tumor cells
The CNNLOH Quantifier method presented here can identify
CNNLOH and quantify the fraction of tumor cells that has
CNNLOH. The method appears to be robust to variations in the
tumor cell content in clinical specimens. However, it would also be
interesting to compare its performance to other methods. To this
end SNP array data was collected from tumor cells in a
microdissected lung cancer sample and from lung cancer tissue
Table 1. Estimation of the fraction of normal cells.
Sample
Fraction of normal cells,
SNP-based
Fraction of normal cells,
counting
367A 0.23 0.29
347A 0.58 0.50
319A 0.23 0.23
234A 0.17 0.20
189A 0.45 0.48
165C 0.42 0.38
39A 0.52 0.55
Comparison between estimates of the fraction of normal cells in Non-Small Cell
Lung Cancer samples using either manual light microscope counting or the SNP
array based method. (see METHODS).
doi:10.1371/journal.pone.0006057.t001
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information we simulated data from mixtures of normal and
tumor cells. In order to measure performance in terms of
sensitivity and specificity we used LOH detected by paired
analysis of the tumor sample and its normal control using dChip in
copy number 2 regions as the gold standard that defined
CNNLOH. We wanted to compare the CNNLOH Quantifier
method to other methods also using allele-specific information.
These methods have been shown to outperform genotype-based
methods [13]. AsCNAR is one such method but the presently
available implementation is not flexible enough to use on this type
of simulated data. On the other hand the SOMATICS method
was designed for data from the Illumina SNP platform, but could
be adapted to analyze simulated data based on data from the
Affymetrix platform. Therefore we chose to compare performance
of the CNNLOH Quantifier method with SOMATICS (see
METHODS for details). Sensitivity and specificity of the methods
for varying mixtures of normal and tumor cells are shown in
figure 5AB. It can be noted that CNNLOH Quantifier has a sharp
increase in sensitivity, above 40% tumor cells, that is due to the
threshold of CNNLOH calling that corresponds to a fraction of
35% tumor cells. CNNLOH Quantifier has a higher sensitivity of
about 90% compared to 60% for SOMATICS for fractions of
tumor larger than about 50% (see Fig. 5A). Specificity is generally
higher for CNNLOH Quantifier compared to SOMATICS (see
Fig. 5B). The sensitivity of SOMATICS was lower than what has
been previously reported for data based on SNP array data from
the Illumina platform [13]. We hypothesized that the SO-
MATICS algorithm performs differently on data generated by
the two platforms. In Gunnarsson et al the same DNA
preparations from CLL tumors were analyzed on both 250K
arrays from Affymetrix and 317K arrays from Illumina [18]. We
analyzed both data sets from 9 CLL tumors with SOMATICS and
found that the algorithm identified more CNNLOH using
Affymetrix data. The ratios of the length of the detected
CNNLOH regions with Affymetrix data compared to Illumina
data range from 1.9 to 36 (see Table S1). These additional regions
of CNNLOH identified using the Affymetrix data may to a large
extent be false positives due to the larger experimental noise. Such
a large number of false positives would be consistent with the low
sensitivity of SOMATICS in detection of CNNLOH in the
simulated data based on Affymetrix data (see Fig. 5A).
Table 2. Validation of CNNLOH estimates using FISH.
Sample SNP-array FISH
6 44% 38%
7 84% 88%
CNNLOH estimates just outside of the chromosome 13q14 region in two CLL
samples based on analysis of SNP data compared with CNNLOH estimates
obtained from FISH analysis on chromosome 13q14 in Gunnarsson et al 2008.
Due to too few regions with deletions in these samples SNP data could not be
used to quantify the fraction of normal cells. Instead flow cytometry data from
Gunnarsson et al 2008 was used to obtain the fraction of normal cells. This
information together with the SNP array data was used to quantify CNNLOH.
doi:10.1371/journal.pone.0006057.t002
Figure 3. Genome-wide quantitation of copy number neutral
tumor LOH. A) Quantitative information on tumor LOH ranging from
black 0% to red 100% for the 22 autosomes for 43 non-small cell lung
cancer samples each representing one row. Deletions are indicated by
green and amplifications in blue. Regions where more than 10% of the
samples in a normal reference set had CNNLOH higher than 0.5 was
removed from the plot (see METHODS). Black arrow indicates an
example of a region on chromosome 11 with a higher frequency of
copy number neutral LOH (52%) than the maximum frequency of 10%
in the normal reference set.
doi:10.1371/journal.pone.0006057.g003
Quantification of LOH
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Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki and was approved by the regional
ethical review board in Uppsala (reference number 2006/325).
The need to obtain individual consent from each patient was
waived by the ethical review board, since most of the patients of
the study population (.90%) were deceased at the start of the
project, the research results did not imply any medical risks, and
the results could not alter the information to the patients, their
families or change management. The procedure is in full
agreement with the Swedish Ethical Review Act.
Tumor samples, histological estimation of tumor cell
content and DNA preparation
Fresh frozen human NSCLCs were obtained from the Uppsala
Fresh Tissue Biobank and used in accordance with the Swedish
biobank legislation. The tumor specimens emanated from patients
from a cohort defined by that they were registered in the Uppsala/
O ¨ rebro lung cancer registry as having NSCLC, had a frozen tissue
sample in the tissue bank and were diagnosed while alive. Case
status was verified by histopathological review and study of
medical records. Hematoxylin-eosin stained cryosections (4 mm)
were prepared from the frozen OCT-embedded tumor tissue
blocks and reviewed microscopically by a surgical pathologist.
Sixty cases with an estimated tumor cell content over 50% were
included in the study. For a subset of these samples (Table 1) we
performed a careful manual counting of tumor and normal cells by
light microscopy using grids in high power magnification fields
(hpf). At least 2000 cells were counted in 5–10 different areas of
the frozen section depending on the size and heterogeneity of the
tumor sample. For each sample genomic DNA was extracted from
5–10 frozen tissue sections (10 mm) using the QIAamp DNA Mini
Kit (Qiagen) according to the manufacturer’s protocol.
Laser Capture Microdissecion of lung cancer samples
Microdissection was performed as previously described with
minor modification [19]. From 5 lung cancer samples, 12 mm
thick cryosections were prepared, transferred to PALM mem-
Figure 4. Tumor LOH analysis is robust to variations in normal cell content in crude tumor samples and enriched tumor
preparations from the same cases. Five tumor samples 13A, 234A, 296A, 319A and 367A were analyzed for tumor LOH using both DNA from
fresh frozen sections of the whole tumor and from laser microdissected portions of the tumor sections with enriched tumor content. The degree of
tumor LOH is indicated for 200 kb chromosmal segments in color ranging from black (0%) to dark red (100%) along the 22 autosomes. Segments
with copy number aberrations are indicated with deletions (green) and amplifications (blue). Note in an enlarged section of chromosome 7 that the
CNNLOH measurements are approxiamately equal in the pairs of whole and microdissected tumor samples.
doi:10.1371/journal.pone.0006057.g004
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to microdissection, sections were thawed and stained with
hematoxylin for 2 minutes followed by fixation in a zinc fixative
for 1 minute and dehydration for 1 minute in 70% and 95%
ethanol respectively. Utilizing the PALM Laser-MicroBeam
System, selected tumor areas containing 6000–10000 cells were
microdissected and transferred by means of a laser puls to 15 ml
DNA extraction buffer ATL (Qiagen) in the cap of a microfuge
tube. DNA extraction was then performed using the QIAamp
DNA Micro Kit according to the manufacturer’s protocol
(Qiagen).
Analysis on Affymetrix 250K SNP arrays
Array experiments were performed according to the standard
protocols for Affymetrix GeneChipH Mapping 250K arrays (Gene
Chip Mapping 500K Assay Manual (P/N 701930 Rev2.),
Affymetrix Inc., Santa Clara, CA). Briefly, total genomic DNA
was digested with a restriction enzyme (Nsp1), ligated to an
Table 3. Quantitation of copy number aberrations and CNNLOH in samples with varying proportions of normal cells.
Sample Segments with CN loss Segments with CN gain Segments with CNNLOH.0.5
13A, N=0.26 264 590 900
13A micro, N=0.11 1349 1502 1226
13A micro/13A 5.0 2.6 1.4
234A, N=0.20 1568 988 831
234A micro, N=0.14 1581 953 808
234A micro/234A 1.0 1.0 1.0
296, N=0.36 16 226 302
296 micro, N=0.02 1958 887 505
296 micro/296A 122 3.9 1.6
319, N=0.23 1036 1823 1274
319 micro, N=0.01 2221 2116 1269
319 micro/319A 2.1 1.2 1.0
367, N=0.23 2446 1324 873
337 micro, N=0.01 2649 2026 593
367 micro/367A 1.1 1.5 0.7
The number of genomic segments with predicted copy number gain or loss is indicated for each sample. The number of segments with CNNLOH larger than 0.5 and no
copy aberrations detected in either analysis are also shown. The ratio of the number of aberrations in the microdissected and whole samples are indicated. For the
samples with large differences in detection of segments with copy number differences, such as 13A, 296A and 319A, the corresponding detection of CNNLOH appears
to be more robust. The proportion of normal cells for each sample is obtained either from manual counting (whole samples) or by the method presented here
(microdissected samples).
doi:10.1371/journal.pone.0006057.t003
Figure 5. Performance of tumor-only analysis using CNNLOH Quantifier and SOMATICS on simulated data corresponding to virtual
mixtures of normal and tumor cells. Data corresponding to varying fractions of normal and tumor cells was simulated using data from normal
cells and microdissected tumor cells from the same lung cancer tumor. The performance of the two algorithms was evaluated as sensitivity (A) and
specificity (B) compared to CNNLOH detected by dChip in a paired analysis of SNP array data of the normal and tumor cells.
doi:10.1371/journal.pone.0006057.g005
Quantification of LOH
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amplification using a single primer. After digestion with DNase I,
the PCR products were labeled with a biotinylated nucleotide
analogue using terminal deoxynucleotidyl transferase and hybrid-
ized to the microarray. Hybridized probes were captured by
streptavidin-phycoerythrin conjugates and finally the arrays were
scanned. Quality control QC, genotype calling and copy number
analyses were made in the Affymetrix GeneChipH Genotyping
Analysis Software (GTYPE) 4.1. The Dynamic Model (DM)
algorithm was used to perform single sample QC. The QC
specification for 250K is a Call Rate .93% using the algorithm
defaults. Subsequent copy number analysis was performed using a
Hidden Markov Model available in the Copy Number Analysis
Tool (CNAT) 4.0.1 with the following parameter settings:
Transition decay 5 Mb, Median normalization and 0.3 Mb
smoothing factor. The reference set used consisted of 96 CEU
samples from the HapMap project (www.hapmap.org/down-
loads/raw_data/affy500k/).
Quantification of the fraction of normal cells
As a first step genomic regions inferred to contain mono-allelic
deletions were identified using the Affymetrix Software CNA 4.0.1
as described above. In order to estimate the fraction of cells with
2N genomic content, C2N, allele-specific information was used.
The Affymetrix SNP raw data was normalized in the software
dChipSNP using the model-based expression method and a
background subtraction method that uses mismatch probes (PM/
MM difference) [6]. The normalized signals were then used to
calculate allelic intensity ratios Ri for each SNP (Ri=B/(A+B)). To
take into account that the same number of A and B alleles may
produce different signals in the assay the allelic ratios were
normalized to allele B frequencies (ABf) for a particular SNP locus
in a given sample by a linear interpolation of the known allele
frequencies for the three genotypes (0, 0.5 and 1.0), as derived and
graphically illustrated in Peiffer et al 2006 [17]. In short the ABf for
a given SNP i was calculated as follows:
if Riv~mABi
ABfi~0:5{mABi{Ri= mABi{mAAi ðÞ   0:5
else
ABfi~0:5zRi{mABi= mBBi{mABi ðÞ   0:5
where Ri is the allelic intensity ratio and mAA,AB,BB are the mean
allelic intensity ratios for a reference population, for the particular
SNP. The reference set was the same as described for copy
number analysis above. Only the SNPs where an AB call was
present in the reference population were used. For the SNPs where
no homozygous calls were available, the mean AA or BB signal for
all SNPs in the samples in the reference population was used
instead.
A histogram of the allele-specific Allele B frequency information
for the markers on each autosome with copy number loss was
computed. The observed histogram was compared to simulated
histograms for varying fractions of C2N. The C2N of the most
similar histogram is the one most likely to have given rise to the
observed data (see Fig. 2). The simulations describe the variation
in ABf due to variation in the signals from A and B alleles by
drawing A and B signals from normal distributions estimated from
regions with copy number 2. The mean and variance for the
distributions were (0, 0.015) for allele A and (0.995, 0.015) for
allele B. The average degree of heterozygosity was estimated from
copy number 2 regions to 36.7%. Simulated ABf values were
calculated as the sum of simulated Allele B signals divided by the
sum of Allele A and B signals from cells composing the virtual
sample. For example when simulating samples with higher
fractions of 2N cells, the proportion of simulated cells with both
A and B signals is also increased. To maintain the average degree
of heterozygosity and to obtain stable histograms they were based
on the ABf values from the uneven number of 14 848 simulated
SNP loci (see more detailed description of choice of settings in
Text S1). Choosing another sufficiently large number of simulated
loci would produce very similar histograms. The histograms were
normalized to unit area to represent the expected pattern for each
of the 200 steps that varied the fraction of C2N cells between 0 and
67%. The smallest Euclidean distance between the observed
histogram and the histograms with varying C2N identified the
fraction most likely to have given rise to the observed Allele B
frequency pattern. Due to the distribution of the ABf values of the
informative markers around 0.5 we chose to use only bins 5 to 16
to increase the weight of their information. To obtain reasonably
well populated and robust histograms, we chose a minimum of 140
markers/chromosome for estimation of C2N. The smallest number
that will give acceptable performance will depend on the
experimental noise of the data and may vary between data sets.
At least two regions on two different chromosomes that varied less
than 5% in their C2N estimates were required for min(C2N)t ob e
used as an estimate of Nnormal (see motivation of choice of settings
in Text S1).
Quantitation of copy number neutral tumor LOH in
tumor-only samples
In the case of CNNLOH it is the fraction of heterozygous cells
Chet that modify the Allele B frequency of the homozygous tumor
cells with LOH. Chet=T het+Nnormal. Histograms were simulated
in the same way as for as above except taking into account the 2N
tumor DNA content and varying Chet between 0 and 91% in 1000
steps. It can be noted that ABf of a tumor sample containing 2N
homozygous tumor cells will be less affected by heterozygous cells
than a sample with 1N tumor cells. These histograms were
compared to normalized histograms based on 2N regions with 140
consecutive markers scanning the diploid regions. The smaller the
window size the larger the risk for false positives. The performance
of the algorithm will also be dependent on the experimental noise
in the data set. We choose a window size of 140 markers to obtain
reasonable resolution and performance on our data set. The
simulated histogram most similar to a particular observed
histogram identified the corresponding fraction of heterozygous
cells, Chet. If the fraction of normal cells Nnormal is known,
Thet=C het2Nnormal and Thom=12Nnormal2Thet. Thus, we can
estimate the fraction of tumor cells with LOH, which is defined as
CNNLOH=Thom/(Thom+Thet). In genomic regions with local
stretches of homozygous SNP genotype calls in the normal cells
the assumption of average homozygosity is violated and a non-
tumor specific CNNLOH signal is detected. In order to avoid
these cases genomic regions with a CNNLOH score higher than
0.5 in 10% or more of the samples of a normal reference set is
removed from the analysis. This is a threshold similar to what has
previously been used [20]. The reference set used was 60 CEU
samples from the HapMap project. A plot of CNNLOH in the 60
reference samples with the regions above the threshold removed is
shown in Figure S1.
Visualization of CNN LOH data
Regions with CNNLOH estimates are mapped to virtual
200 kb genomic regions for each chromosome in each sample. In
order to illustrate the tumor LOH information from several
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least one sample are visualized using the DIGMAP software [21].
The virtual probes without LOH information are assigned the
average value of neighboring probes with information. Copy
number information for the virtual probes is overlaid the tumor
LOH information.
Simulations and analyis of SNP array data from mixtures
of normal cells and tumor cells
SNP array data including Log2- and Allele B frequency values
from the microdissected lung cancer sample 13A and the
corresponding normal genomic DNA called 13C from the
surrounding normal lung tissue was collected. The Allele B
frequency data for virtual mixtures of these two samples (from 0%
to 100% in 5% steps) was simulated by linear interpolation for
each marker. Log2-values and copy number information from the
microdissected tumor sample was used for all virtual samples.
CNNLOH Quantifier and SOMATICS was used to analyze the
simulated data. The results were compared to a gold standard
which was the LOH detected in copy number 2 regions in a paired
analysis of the tumor sample 13A and the paired control 13C using
dChip. All markers in copy number 2 regions with an ABf-pattern
corresponding to 35% homozygous cells or higher were consid-
ered as CNNLOH for the CNNLOH Quantifier algorithm.
Markers detected as CNNLOH in more than 10% of a set of 60
reference samples from the HapMap project were regarded as
false positives and removed from the analysis. Sensitivity and
specificity of detection was measured for SOMATICS and
CNNLOH Quantifier.
Data and software
All microarray data reported here is described in accordance
with MIAME guidelines and has been made publicly available
through GEO with the accession number GSE16092. Computer
code written in MATLAB is available from the authors upon
request.
Discussion
Identification of informative SNPs
A key issue in detection of LOH and quantification of genomic
aberrations in tumor samples is to identify the informative SNPs.
The informative SNPs are those that are heterozygous in the
normal cells of the patient. These markers can loose their
heterozygosity and their allele frequency is dependent on the
relative proportions of heterozygous normal and tumor cells, and
tumor cells that have undergone LOH. In the case of paired
analysis, a normal sample is available and the informative SNPs
are those that are heterozygous in this sample. It is more difficult
to identify the informative SNPs in a tumor-only analysis when the
genotype of the normal sample is unknown.
One recently developed tool, AsCNAR, identifies the informa-
tive SNPs as those that are called heterozygous in the tumor
sample [12]. This is a simple and efficient strategy in the common
cases where there is a significant proportion of normal cells in the
tumor sample. Another tool SOMATICs identifies informative
SNPs based on statistical considerations. However, both of these
tools have difficulty analyzing tumor samples with a low degree of
heterogeneity, when the informative SNPs are difficult to
distinguish from the uninformative ones. In contrast, CNNLOH
Quantifier does not suffer from the same limitations, since it does
not rely on identification of informative SNPs. Instead it uses a
fixed average heterozygosity rate estimated from samples in a
reference population. The risk that the fixed heterozygosity rate is
not appropriate for every studied region in a particular sample
appears to be small, since few regions are identified as having
LOH in our reference population of normal samples. However,
for all tumor-only methods including CNNLOH Quantifier it is
difficult to exclude CNNLOH signals due to regions with
homozygous markers in the constitutive DNA in pure tumor
samples. CNNLOH Quantifier handles this issue by removing
regions with more than 10% of the reference samples exceeding a
35% or 50% CNNLOH threshold from further analysis. However,
even with such a threshold, CNNLOH signals due to signals from
constitutive DNA may occur. Therefore we suggest validating
CNNLOH findings in constitutive DNA when available. A
possible improvement to the method described here could be to
use a variable heterozygosity rate based on a moving average from
the reference data set, but this has not been investigated further.
Copy number information is required to interpret allele
frequency information
Another fundamental feature of the algorithm described here is
the need to have access to correct copy number information
because it determines how much the SNP signal information is
going to be affected by genetically normal cells. The Allele B
frequency is affected more in regions with copy number one than
with copy number 2 because the alleles from the normal cells
constitute a larger proportion of all alleles. When estimating tumor
heterogeneity using CNNLOH Quantifier an implicit assumption
is made that there is only one type of genomic aberration at each
locus. Although an important theoretical limitation, potential
additional genomic aberrations appear to be small in magnitude or
rare events in practice, at least in the tumors we studied, since the
validation experiments indicate good accuracy of the method. One
explanation is that many genomic aberrations provide a
proliferation advantage. Thus, the cells containing these aberra-
tions will become more frequent during tumor development than
cells with other aberrations at the same locus not promoting
proliferation or doing so to a lower extent.
The sensitivity to variation in normal cell content exhibited by
current algorithms for detection of copy number aberrations in
tumor cells, such as CNAT 4.0.1 used here, presents a more
serious problem (see Fig. 4 and Table 3). Failure to adequately
detect copy number aberrations provides inaccurate input data for
the quantification of normal cells and CNNLOH. Undetected
deletions will reduce the available information on which to base
the quantification of normal cells on and may preclude
determining the fraction of normal cells in some samples. For
quantitation of CNNLOH undetected copy number 1 regions will
be analyzed as copy number 2 regions and will therefore receive
exaggerated estimates of CNNLOH. However, the deletions that
are detected appear to be correct, since the estimates of normal
cell content are in agreement with those based on microscopic cell
count.
The evaluation of the performance of the CNNLOH Quantifier
method indicates that it has a higher sensitivity than SOMATICS
at least on data generated using Affymetrix SNP arrays (see
Fig. 5A). The difference in performance of the SOMATICS
algorithm depending on the data source may be explained by
previously shown differences in experimental noise between data
generated on the two platforms [18]. The SOMATICS algorithm
identifies informative SNPs by statistical methods which becomes
more difficult in the more noisy Affymetrix data. The CNNLOH
Quantifier algorithm does not identify each informative SNP but
studies the pattern of a group of consecutive SNPs and thus is
more robust to experimental noise. The downside of studying a
group of SNPs is that the method sometimes identifies too many
Quantification of LOH
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Fig. 5B).
Summary
In this study we provide a novel algorithm, CNNLOH
Quantifier, for genome-wide quantification of CNNLOH from
SNP array data. We demonstrate that the fraction of normal cells
in tumor samples, as well as copy number neutral LOH, can be
accurately estimated in tumor cells. Since the use of SNP array
data provides genome-wide information, it will now be possible to
quantify common and rare events of CNNLOH in tumor cells
from samples containing normal cells. Our algorithm may also be
applied to screen for biomarkers that may be used for early
detection of cancer. Additionally, this tool can be used to monitor
how rapidly cells with a particular genomic aberration increase in
a population of tumor cells during tumorigenesis. Given the
complex nature of clinical tumor biobank material that forms the
basis for translational cancer research, the development of
bioinformatic tools that can process data from heterogeneous
tumor samples with varying fractions of normal cells is of great
importance.
Supporting Information
Figure S1 Quantification of CNNLOH in the normal reference
samples Quantitation of copy number neutral LOH in the 60
normal reference samples. Regions with CNNLOH above 0.5 in
more than 10% of the samples have been removed. Note that
allelic patterns of CNNLOH are present in several regions in
individual samples. Thus, frequently recurring CNNLOH in
tumor cells can be identified, while it is difficult to identify an
individual tumor-specific CNNLOH event in an individual tumor
sample.
Found at: doi:10.1371/journal.pone.0006057.s001 (1.30 MB TIF)
Table S1 Size of the regions detected as CNNLOH using
SOMATICS on Affymetrix and Illumina data from 9 Chronic
Lymphocytic Leukemia samples described in Gunnarsson et al
[18]. Ratio of the length of regions detected on Affymterix and
Illimina data. Note that SOMATICS detects more CNNLOH
using Affymetrix data than with Illumina data.
Found at: doi:10.1371/journal.pone.0006057.s002 (0.03 MB
DOC)
Text S1 Choice of settings.
Found at: doi:10.1371/journal.pone.0006057.s003 (0.03 MB
DOC)
Acknowledgments
The support of the Uppsala Lung Cancer Study Group is gratefully
acknowledged.
Author Contributions
Conceived and designed the experiments: HG AI. Performed the
experiments: KE MR JB. Analyzed the data: HG MR JW JB AI.
Contributed reagents/materials/analysis tools: SE MB APT ML RR LH
PM JB AI. Wrote the paper: HG KE AI.
References
1. Huang J, Wei W, Chen J, Zhang J, Liu G, et al. (2006) CARAT: a novel method
for allelic detection of DNA copy number changes using high density
oligonucleotide arrays. BMC Bioinformatics 7: 83.
2. Ishikawa S, Komura D, Tsuji S, Nishimura K, Yamamoto S, et al. (2005) Allelic
dosage analysis with genotyping microarrays. Biochem Biophys Res Commun
333: 1309–1314.
3. Komura D, Shen F, Ishikawa S, Fitch KR, Chen W, et al. (2006) Genome-wide
detection of human copy number variations using high-density DNA
oligonucleotide arrays. Genome Res 16: 1575–1584.
4. Laframboise T, Harrington D, Weir BA (2007) PLASQ: a generalized linear
model-based procedure to determine allelic dosage in cancer cells from SNP
array data. Biostatistics 8: 323–336.
5. LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, et al. (2005) Allele-
specific amplification in cancer revealed by SNP array analysis. PLoS Comput
Biol 1: e65.
6. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, et al. (2004) dChipSNP:
significance curve and clustering of SNP-array-based loss-of-heterozygosity data.
Bioinformatics 20: 1233–1240.
7. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, et al. (2005) A robust
algorithm for copy number detection using high-density oligonucleotide single
nucleotide polymorphism genotyping arrays. Cancer Res 65: 6071–6079.
8. Zhao X, Li C, Paez JG, Chin K, Janne PA, et al. (2004) An integrated view of
copy number and allelic alterations in the cancer genome using single nucleotide
polymorphism arrays. Cancer Res 64: 3060–3071.
9. Micke P, Ostman A (2005) Exploring the tumour environment: cancer-
associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9:
1217–1233.
10. Lamy P, Andersen CL, Dyrskjot L, Torring N, Wiuf C (2007) A Hidden Markov
Model to estimate population mixture and allelic copy-numbers in cancers using
Affymetrix SNP arrays. BMC Bioinformatics 8: 434.
11. Nancarrow DJ, Handoko HY, Stark MS, Whiteman DC, Hayward NK (2007)
SiDCoN: A Tool to Aid Scoring of DNA Copy Number Changes in SNP Chip
Data. PLoS ONE 2: e1093.
12. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, et al. (2007) Highly
sensitive method for genomewide detection of allelic composition in nonpaired,
primary tumor specimens by use of affymetrix single-nucleotide-polymorphism
genotyping microarrays. Am J Hum Genet 81: 114–126.
13. Assie G, LaFramboise T, Platzer P, Bertherat J, Stratakis CA, et al. (2008) SNP
arrays in heterogeneous tissue: highly accurate collection of both germline and
somatic genetic information from unpaired single tumor samples. Am J Hum
Genet 82: 903–915.
14. Fitzgibbon J, Smith LL, Raghavan M, Smith ML, Debernardi S, et al. (2005)
Association between acquired uniparental disomy and homozygous gene
mutation in acute myeloid leukemias. Cancer Res 65: 9152–9154.
15. Langdon JA, Lamont JM, Scott DK, Dyer S, Prebble E, et al. (2006) Combined
genome-wide allelotyping and copy number analysis identify frequent genetic
losses without copy number reduction in medulloblastoma. Genes Chromo-
somes Cancer 45: 47–60.
16. Andersen CL, Wiuf C, Kruhoffer M, Korsgaard M, Laurberg S, et al. (2007)
Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis
28: 38–48.
17. Peiffer DA, Le JM, Steemers FJ, Chang W, Jenniges T, et al. (2006) High-
resolution genomic profiling of chromosomal aberrations using Infinium whole-
genome genotyping. Genome Res 16: 1136–1148.
18. Gunnarsson R, Staaf J, Jansson M, Ottesen AM, Go ¨ransson H, et al. (2008)
Screening for copy number alterations and loss of heterozygosity in chronic
lymphocytic leukemia - Acomparative study of four differently designed high
resolution microarray platforms. Genes Chromosomes Cancer 47: 697–711.
19. Micke P, Ostman A, Lundeberg J, Ponte ´n F (2005) Laser-assisted cell
microdissection using the PALM system. Methods Mol Biol 293: 151–166.
20. Beroukhim R, Lin M, Park Y, Hao K, Zhao X, et al. (2006) Inferring loss-of-
heterozygosity from unpaired tumors using high-density oligonucleotide SNP
arrays. PLoS Comput Biol 2: e41.
21. Yi Y, Mirosevich J, Shyr Y, Matusik R, George AL Jr (2005) Coupled analysis of
gene expression and chromosomal location. Genomics 85: 401–412.
Quantification of LOH
PLoS ONE | www.plosone.org 10 June 2009 | Volume 4 | Issue 6 | e6057